Abstract:Background: Chronic use of mu-opioid receptor agonists paradoxically causes both hyperalgesia and the loss of analgesic efficacy. Opioid treatment increases presynaptic N-methyl-d-aspartate receptor activity to potentiate nociceptive input to spinal dorsal horn neurons. However, the mechanism responsible for this opioid- induced activation of presynaptic N-methyl-d-aspartate receptors remains unclear. alpha 2 delta-1, formerly known as a calcium channel subunit, interacts with N-methyl-d-aspartate receptors and is primarily expressed at presynaptic terminals. This study tested the hypothesis that alpha 2 delta-1-bound N-methyl-d-aspartate receptors contribute to presynaptic N-methyl-d-aspartate receptor hyperactivity associated with opioid-induced hyperalgesia and analgesic tolerance. Methods: Rats (5 mg/kg) and wild-type and alpha 2 delta-1-knockout mice (10 mg/kg) were treated intraperitoneally with morphine twice/day for 8 consecutive days, and nociceptive thresholds were examined. Presynaptic N-methyl-d-aspartate receptor activity was recorded in spinal cord slices. Coimmunoprecipitation was performed to examine protein-protein interactions. Results: Chronic morphine treatment in rats increased alpha 2 delta-1 protein amounts in the dorsal root ganglion and spinal cord. Chronic morphine exposure also increased the physical interaction between alpha 2 delta-1 and N-methyl-d-aspartate receptors by 1.5 +/- 0.3 fold (means +/- SD, P = 0.009, n = 6) and the prevalence of alpha 2 delta-1-bound N-methyl-d-aspartate receptors at spinal cord synapses. Inhibiting alpha 2 delta-1 with gabapentin or genetic knockout of alpha 2 delta-1 abolished the increase in presynaptic N-methyl-d-aspartate receptor activity in the spinal dorsal horn induced by morphine treatment. Furthermore, uncoupling the alpha 2 delta-1-Nmethyl- d-aspartate receptor interaction with an alpha 2 delta-1 C terminus-interfering peptide fully reversed morphine-induced tonic activation of N-methyl-d-aspartate receptors at the central terminal of primary afferents. Finally, intraperitoneal injection of gabapentin or intrathecal injection of an alpha 2 delta-1 C terminus-interfering peptide or alpha 2 delta-1 genetic knockout abolished the mechanical and thermal hyperalgesia induced by chronic morphine exposure and largely preserved morphine's analgesic effect during 8 days of morphine treatment. Conclusions: alpha 2 delta-1-Bound N-methyl-d-aspartate receptors contribute to opioid-induced hyperalgesia and tolerance by augmenting presynaptic N-methyl-d-aspartate receptor expression and activity at the spinal cord level.

Aconitum-Derived Bulleyaconitine A Exhibits Antihypersensitivity Through Direct Stimulating Dynorphin A Expression in Spinal Microglia

Aconitum-derived bulleyaconitine A exhibits anti-hypersensitivity through direct stimulating dynorphin A expression in spinal microglia.

Bulleyaconitine A Inhibits Visceral Nociception and Spinal Synaptic Plasticity through Stimulation of Microglial Release of Dynorphin A

Bulleyaconitine A Inhibits Morphine-Induced Withdrawal Symptoms, Conditioned Place Preference, and Locomotor Sensitization Via Microglial Dynorphin A Expression

Bulleyaconitine A inhibits morphine physical and psychological dependence via dynorphin A expression

Molecular Signaling Underlying Bulleyaconitine A (Baa)-Induced Microglial Expression of Prodynorphin

Concurrent Bullatine A Enhances Morphine Antinociception and Inhibits Morphine Antinociceptive Tolerance by Indirect Activation of Spinal Κ-Opioid Receptors.

Oral application of bulleyaconitine A attenuates morphine tolerance in neuropathic rats by inhibiting long-term potentiation at C-fiber synapses and protein kinase C gamma in spinal dorsal horn

Bulleyaconitine A Exerts Antianxiety and Antivisceral Hypersensitivity Effects.

Mechanisms for Therapeutic Effect of Bulleyaconitine A on Chronic Pain

Mechanisms for therapeutic effect of bulleyaconitine A on chronic pain.

Ester Hydrolysis Differentially Reduces Aconitine-Induced Anti-hypersensitivity and Acute Neurotoxicity: Involvement of Spinal Microglial Dynorphin Expression and Implications for Aconitum Processing

Bulleyaconitine A attenuates hyperexcitability of dorsal root ganglion neurons induced by spared nerve injury: The role of preferably blocking Nav1.7 and Nav1.3 channels

Bullatine A Stimulates Spinal Microglial Dynorphin A Expression to Produce Anti-Hypersensitivity in a Variety of Rat Pain Models.

Bulleyaconitine A preferably reduces tetrodotoxin-sensitive sodium current in uninjured dorsal root ganglion neurons of neuropathic rats probably via inhibition of protein kinase C.

Interactions of the potent D-amino acid oxidase inhibitor CBIO with morphine in pain and tolerance to analgesia.

Lappaconitine, a C18-diterpenoid alkaloid, exhibits antihypersensitivity in chronic pain through stimulation of spinal dynorphin A expression

Bulleyaconitine A depresses neuropathic pain and potentiation at C-fiber synapses in spinal dorsal horn induced by paclitaxel in rats

Comparison of analgesic activities of aconitine in different mice pain models

Α2δ-1–Boundn-methyl-d-aspartate Receptors Mediate Morphine-induced Hyperalgesia and Analgesic Tolerance by Potentiating Glutamatergic Input in Rodents

[Effect of Intrathecal Injection of Dopamine Receptor Agonists/antagonists on Pain and Acupuncture Analgesia in Rats].